Many emerging cell and gene therapy companies hesitate to enter supply agreements because they believe they are too small, too early-stage, or need maximum flexibility. Some worry that agreements will lock them into long-term pricing or make it harder to adapt as their processes evolve.
These concerns are understandable, particularly for organizations navigating clinical growth, evolving forecasts, and limited resources. However, many companies underestimate the operational value that supply agreements can provide, especially in highly specialized and regulated industries like cell therapy, tissue banking, and regenerative medicine.
In advanced therapies, supply agreements are not simply purchasing tools. They are one of the most important mechanisms for protecting continuity of supply.
Supply continuity depends on visibility
Many of the products used in advanced therapies rely on specialized materials, controlled manufacturing processes, and coordinated production planning. Suppliers cannot effectively prepare for future demand without some level of forecasting visibility from customers.
This is where supply agreements become important.
When suppliers understand anticipated demand, they are better positioned to:
- plan production capacity
- secure raw materials
- maintain protected inventory levels
- reduce lead time volatility
- support customers during periods of disruption
Without this visibility, supply chains become more reactive, particularly during periods of constrained supply or unexpected disruption.
Emerging companies often misunderstand flexibility
One of the most common misconceptions surrounding supply agreements is the belief that they eliminate operational flexibility.
Well-structured agreements are often designed specifically to support evolving organizations. Forecasts can be adjusted. Volumes can scale over time. Product configurations can evolve as programs mature.
The goal is not rigidity. The goal is to plan alignment between customer and supplier.
Many concerns surrounding supply agreements stem from understandable assumptions, particularly for organizations navigating clinical growth and evolving demand forecasts. However, operational reality often looks very different in practice.
Common Concern | Operational Reality |
“We are too small for a supply agreement.” | Emerging companies are often the most vulnerable during supply shortages and allocation events. Early planning visibility helps suppliers better support continuity as programs grow. |
“A supply agreement will lock us into long-term pricing.” | Well-structured agreements can include flexibility for changing volumes, evolving forecasts, and future pricing discussions. Their primary purpose is continuity planning, not pricing rigidity. |
“We may need to change configurations as our process evolves.” | Supply agreements can be structured to accommodate product evolution and process refinement over time. |
“We are not commercial yet, so we do not need one.” | Continuity planning becomes important long before commercialization. Early collaboration helps suppliers prepare inventory, raw materials, and production capacity to support future growth. |
“We need maximum flexibility right now.” | True operational flexibility often comes from preparation and supplier alignment, not reactive purchasing during disruption. |
“We can always place orders when we need product.” | During constrained supply events, suppliers must prioritize inventory and production allocation. Customers with established planning relationships are often easier to support consistently. |
Strong supply chains are rarely built reactively. They are built through planning, communication, and long-term operational alignment.
Supply protection requires preparation
Strong supply chains are rarely built reactively. They are built through planning, communication, and long-term operational alignment.
Suppliers can only reserve capacity, protect inventory, and prepare for disruption when they have confidence in future customer demand. Supply agreements help create that confidence.
For advanced therapy organizations operating in regulated, high-stakes environments, this planning can become increasingly important as programs scale and operational complexity grows.
A strategic operational tool
As the advanced therapy industry continues to mature, supply continuity is becoming more closely connected to operational stability, manufacturing reliability, and long-term scalability.
Companies that approach supplier relationships strategically often place greater emphasis on visibility, planning, and continuity rather than treating supply strictly as a transactional procurement activity.
Supply agreements support that approach by creating stronger alignment between suppliers and customers before disruptions occur, not during them.
In industries where consistency and continuity matter, that preparation can make a meaningful difference.
At Instant Systems, we work closely with customers to build supply strategies that support long-term continuity, operational flexibility, and scalable growth. Our experience supporting highly regulated advanced therapy environments has reinforced the importance of planning ahead, maintaining strong supplier relationships, and protecting supply before disruptions occur.
Because when therapies depend on consistency, continuity cannot be left to chance.
